To analyze the gene sensitivity to antihypertensive drugs, conduct gene-oriented selection of individualized medications, and give accurate drug treatment for patients with hypertension.

One hundred and fifty-seven incipient hypertension patients were included from January 2016 to September 2017 and divided into either a study group (54 cases) or a control group (103 cases). All patients in the study group underwent genetic testing for gene sensitivity to antihypertensive drugs, and antihypertensive drugs were selected according to the results of gene testing. In the control group, antihypertensive drugs were selected empirically. Clinical efficacy of antihypertensive drugs were compared between the two groups. Drug sensitivity is expressed as composition ratio. The t-test was used to compare age, body mass index, liver and kidney function, blood lipids, blood pressure, heart rate, blood pressure stability time and drug types among the groups, and gender and the number of adverse reactions were compared using the chi-square test.

Of the 54 cases in the study group, 98.1% were sensitive to CCB, 70.3% sensitive to beta-blockers, 70.3% to ACEI, and no patients were sensitive to ARB and diuretics. After treatment, blood pressure decreased in both groups, the normal blood pressure time in the study group and control group was (4.58±1.17) vs (5.14±1.03) (P<0.05), and the number of drugs used was (1.48±0.50) vs (1.52±0.52) (t=-0.18, P=0.86). The adverse reactions of antihypertensive drugs between the two groups had no statistical significance (P>0.05). Heart rate decreased significantly in the study group compared with the control group [(68.33±1.62) vs (74.54±2.14, P<0.05].

Hypertension patients requiring antihypertensive drug treatment can choose CCB and beta-blockers based on gene testing results. Gene-oriented individualized selection of antihypertensive drugs is more conducive to the control of blood pressure.